<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480571</url>
  </required_header>
  <id_info>
    <org_study_id>BL-1020 II</org_study_id>
    <nct_id>NCT00480571</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder</brief_title>
  <official_title>An Open-label, Multi-center, 6-week, Sequential Cohort Study Designed to Determine the Safety and Tolerability of Two Dose Ranges of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-affective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLineRx, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLineRx, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, multi-center, 6-week, sequential cohort study designed to determine the safety
      and tolerability of two dose ranges of BL-1020 in hospitalized subjects with chronic
      schizophrenia or schizo-affective disorder
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and tolerability of two dose ranges (20-40 mg/day, 30-50 mg/day) of BL-1020 tri-mesylate (free base) in subjects with chronic schizophrenia or schizo-affective disorder</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the MTD, the optimal dose escalation schedule, and the maximum tolerated maintenance dose</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of the two dose ranges of BL-1020</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetics of BL-1020 and its metabolites</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BL 1020 low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BL 1020 High Dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BL-1020</intervention_name>
    <description>BL-1020 Low Dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BL 1020 High Dose</intervention_name>
    <description>BL 1020 High Dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  18 to 65 years of age, inclusive

          -  meet criteria for chronic (diagnosis established &gt; 1 year ago) schizophrenia with
             adequate psychotic symptoms as demonstrated by a PANSS total score &gt; 60

          -  current diagnosis of schizophrenia (disorganized type, 295.10; catatonic type, 295.20;
             paranoid type, 295.30; undifferentiated type, 295.90) or schizoaffective disorder
             (295.7) in accordance with DSM-IV

          -  Agree to be fully hospitalized until at least Day 14 of the study

          -  Females must be of non-childbearing potential: surgically sterilized (i.e. tubal
             ligation), have had a hysterectomy prior to the screening phase, or be
             post-menopausal. Females who have been post-menopausal for more than 12 months but
             less than 24 months must have a FSH &gt; 40 mU/mL.

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  administration of clozapine within 60 days prior to Baseline

          -  DSM-IV diagnosis of schizophreniform disorder (295.40) or schizophrenia residual
             sub-type (295.60), or other primary psychiatric diagnoses, such as bipolar disorder or
             major depressive disorder

          -  Severity of psychosis rated severe or higher (CGI-S 6 or 7)

          -  Known suicidal risk (modified ISST score&gt;7)

          -  Requiring disallowed concomitant psychotropic medication following enrolment into the
             study

          -  Current evidence of clinically significant or unstable illness

          -  Clinically significant abnormal laboratory data (e.g. creatinine, AST or ALT greater
             than 3 x the upper limit of normal, TSH&gt;10 IU) at screening, or any abnormal
             laboratory values that could interfere with the assessment of safety (e.g. blood cell
             count, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Davidson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Psychiatry, Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Psychiatry, Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenţǎ Militar Central &quot;Dr Carol Davila&quot;,</name>
      <address>
        <city>Bucharest</city>
        <state>Str Mircea Vulcǎnescu 18</state>
        <zip>010811</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2007</study_first_submitted>
  <study_first_submitted_qc>May 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2007</study_first_posted>
  <last_update_submitted>July 20, 2009</last_update_submitted>
  <last_update_submitted_qc>July 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>BioLineRx</name_title>
    <organization>Drug Development Company</organization>
  </responsible_party>
  <keyword>chronic schizophrenia or schizo-affective disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

